Comparative Pharmacology
Head-to-head clinical analysis: BREXPIPRAZOLE versus SEPHIENCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREXPIPRAZOLE versus SEPHIENCE.
BREXPIPRAZOLE vs SEPHIENCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.
SEPHIENCE (pegfilgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) analog. It binds to G-CSF receptors on hematopoietic cells, stimulating proliferation, differentiation, and release of neutrophils from bone marrow.
Oral: 1 mg once daily initially, titrate to 2 mg once daily after 3-7 days, then to 4 mg once daily based on response; maximum 4 mg once daily.
Adults: 200 mg orally twice daily with food.
None Documented
None Documented
91 hours (range 70–120 hours) for the parent drug; repeated dosing leads to steady state in ~3–4 weeks. The active metabolite DM-3411 has a half-life of ~86 hours.
Clinical Note
moderateBrexpiprazole + Haloperidol
"The serum concentration of Haloperidol can be increased when it is combined with Brexpiprazole."
Clinical Note
moderateBrexpiprazole + Methylphenidate
"The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Methylphenidate."
Clinical Note
moderateBrexpiprazole + Quinagolide
"The therapeutic efficacy of Quinagolide can be decreased when used in combination with Brexpiprazole."
Clinical Note
moderateTerminal elimination half-life is 12-15 hours in healthy adults, allowing for twice-daily dosing. Half-life may be prolonged in renal impairment (up to 30 hours in severe cases).
Primarily hepatic metabolism via CYP3A4 and CYP2D6; ~25% renal excretion (mostly as metabolites), ~60% fecal excretion (mostly as metabolites).
SEPHIENCE is primarily eliminated via renal excretion (approximately 70% as unchanged drug) and biliary/fecal excretion (approximately 25% as metabolites and unchanged drug).
Category A/B
Category C
Atypical Antipsychotic
Atypical Antipsychotic
Brexpiprazole + Sulfisoxazole
"The serum concentration of Sulfisoxazole can be increased when it is combined with Brexpiprazole."